The present work shows a novel binding activity of the tumor specific lectin—recombinant human galectin-1 (hGal-1)—to three porphyrin compounds: (1) Zn-porphyrin (ZnTPPS); (2) Mn-porphyrin and (3) Au-porphyrin. These compounds are widely applied in the photodynamic therapy of cancer (PDT). Our data indicate that hGal-1, similar to some plant lectins, a bacterial lectin from Pseudomonas aeruginosa and an animal lectin from Helix pomatia, possesses dual functions binding to both carbohydrate and non-carbohydrate ligands. The interaction of ZnTPPS with hGal-1 was studied by the specific fluorescence emission of the porphyrin. The protein binding properties to Mn/Au-porphyrins and adenine were measured by intrinsic protein fluorescence quenching. The values determined for the apparent dissociation constants (K_D) of 0.6–1.5 μM are similar to the K_D for complexes of concanavalin A and porphyrin, and are indicative of the high affinity of hGal-1 for these porphyrins. In addition, the analysis of the hyperbolic binding curves obtained suggests the presence of one hGal-1 binding site for porphyrins or adenine. Additionally, we found that hGal-1 interacts with the fluorescent probe 2-(p-toluidinyl)naphthalene sulfonic acid (TNS), that was used to identify the hydrophobic regions within hGal-1. Homodimeric hGal-1 has more than one class of binding site for TNS as revealed by the sigmoidal shape of the fluorescence titration curve. hGal-1 can be characterized as a porphyrin-binding protein based on its interactions with the Zn/Mn- and Au-porphyrins, and this indicates that hGal-1 may have potential as a delivery molecule to target systems (e.g., tumor cells) with possible application in photodynamic therapy.

We addressed the issue of C1q autoantigenicity by studying the structural features of the autoepitopes recognized by the polyclonal anti-C1q antibodies present in Lupus Nephritis (LN) sera. We used six fractions of anti-C1q as antigens and selected anti-idiotypic scFv antibodies from the phage library “Griffin.1”. The monoclonal scFv A1 was the most potent inhibitor of the recognition of C1q and its fragments ghA, ghB and ghC, comprising the globular domain gC1q, by the lupus autoantibodies. It was sequenced and in silico folded by molecular dynamics into a 3D structure. The generated 3D model of A1 elucidated CDR similarity to the apical region of gC1q, thus mapping indirectly for the first time a globular autoepitope of C1q. The V_H CDR2 of A1 mimicked the ghA sequence GSEAD suggested as a cross-epitope between anti-DNA and anti-C1q antibodies. Other potential inhibitors of the recognition of C1q by the LN autoantibodies among the selected recombinant antibodies were the monoclonal scFv F6, F9 and A12.